Sarepta Therapeutics, Inc.
SRPT
$20.22
$0.160.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 68.38% | 80.15% | 65.94% | 40.79% | 38.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.38% | 80.15% | 65.94% | 40.79% | 38.93% |
| Cost of Revenue | 59.19% | 263.02% | 38.62% | 36.68% | -18.76% |
| Gross Profit | 83.24% | -202.24% | 107.63% | 50.26% | 1,038.66% |
| SG&A Expenses | -0.65% | 5.22% | 24.43% | 6.04% | 17.06% |
| Depreciation & Amortization | 10.98% | 0.00% | -21.23% | 37.13% | 235.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.27% | 176.11% | 33.47% | 26.18% | -7.88% |
| Operating Income | 16,587.45% | -960.58% | 556.57% | 206.50% | 99.47% |
| Income Before Tax | 1,031.60% | -1,025.30% | 325.41% | 202.51% | 193.09% |
| Income Tax Expenses | -707.76% | 1,100.79% | 340.23% | -94.91% | -23.92% |
| Earnings from Continuing Operations | 2,947.86% | -1,338.98% | 248.37% | 182.10% | 126.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,947.86% | -1,338.98% | 248.37% | 182.10% | 126.98% |
| EBIT | 16,587.45% | -960.58% | 556.57% | 206.50% | 99.47% |
| EBITDA | 1,476.67% | -765.33% | 378.20% | 422.80% | 106.53% |
| EPS Basic | 2,841.43% | -1,296.02% | 238.71% | 176.53% | 125.32% |
| Normalized Basic EPS | 4,068.18% | -853.34% | 451.14% | 221.52% | 101.92% |
| EPS Diluted | 2,662.81% | -1,347.63% | 245.20% | 173.55% | 125.30% |
| Normalized Diluted EPS | 3,913.69% | -894.42% | 407.56% | 215.46% | 101.83% |
| Average Basic Shares Outstanding | 3.58% | 3.59% | 2.85% | 7.31% | 6.62% |
| Average Diluted Shares Outstanding | 7.54% | -1.77% | 11.67% | 13.00% | 11.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |